Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]
Discontinued
Reference number: GID-TAG482
This appraisal remains suspended following an update from the company (Novartis). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia. NICE will continue to monitor for any developments and will provide an update when necessary.